Literature DB >> 20632962

Therapeutic potential of vasoactive intestinal peptide and its receptors in neurological disorders.

Caitlin M White1, Sunggoan Ji, Huan Cai, Stuart Maudsley, Bronwen Martin.   

Abstract

Vasoactive intestinal peptide (VIP) is a basic 28 amino acid peptide that binds to a member of the class II family of G protein-coupled receptors (GPCRs). It is widely expressed throughout the body and plays an important role in numerous biological functions. VIP acts via three different GPCRs: VPAC1, VPAC2, and PAC1, which have been identified in various tissues, including brain, lung, kidney, gastrointestinal tract, tongue, and also on immunocompetent cells such as macrophages and lymphocytes. There is mounting evidence that VIP expression and signaling is altered in numerous neurological disorders, and it is becoming apparent that VIP and its receptors could be therapeutic loci for the treatment of several pathological conditions of the central nervous system. In this review, we describe the pathology of several major neurological disorders and discuss the potential pharmacotherapeutic role of VIP and its receptors for the treatment of disorders such as Alzheimer's disease, Parkinson's disease, and Autism Spectrum Disorders.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20632962      PMCID： PMC2967653          DOI： 10.2174/187152710793361595

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN： 1871-5273            Impact factor:   4.388


  60 in total

1.  Differential activation of phospholipase D by VPAC and PAC1 receptors.

Authors:  D A McCulloch; E M Lutz; M S Johnson; C J MacKenzie; R Mitchell
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

2.  Dissociation between light-induced phase shift of the circadian rhythm and clock gene expression in mice lacking the pituitary adenylate cyclase activating polypeptide type 1 receptor.

Authors:  J Hannibal; F Jamen; H S Nielsen; L Journot; P Brabet; J Fahrenkrug
Journal:  J Neurosci       Date:  2001-07-01       Impact factor: 6.167

Review 3.  Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions.

Authors:  D Vaudry; B J Gonzalez; M Basille; L Yon; A Fournier; H Vaudry
Journal:  Pharmacol Rev       Date:  2000-06       Impact factor: 25.468

4.  Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation.

Authors:  K B Nelson; J K Grether; L A Croen; J M Dambrosia; B F Dickens; L L Jelliffe; R L Hansen; T M Phillips
Journal:  Ann Neurol       Date:  2001-05       Impact factor: 10.422

5.  Enhanced delayed-type hypersensitivity and diminished immediate-type hypersensitivity in mice lacking the inducible VPAC(2) receptor for vasoactive intestinal peptide.

Authors:  E J Goetzl; J K Voice; S Shen; G Dorsam; Y Kong; K M West; C F Morrison; A J Harmar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-06       Impact factor: 11.205

6.  In vitro evaluation of VIP/PACAP receptors in healthy and diseased human tissues. Clinical implications.

Authors:  J C Reubi
Journal:  Ann N Y Acad Sci       Date:  2000       Impact factor: 5.691

7.  A study of novel polymorphisms in the upstream region of vasoactive intestinal peptide receptor type 2 gene in autism.

Authors:  E Asano; H Kuivaniemi; A H Huq; G Tromp; M Behen; R Rothermel; J Herron; D C Chugani
Journal:  J Child Neurol       Date:  2001-05       Impact factor: 1.987

8.  Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease.

Authors:  D Offen; Y Sherki; E Melamed; M Fridkin; D E Brenneman; I Gozes
Journal:  Brain Res       Date:  2000-01-31       Impact factor: 3.252

Review 9.  Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator.

Authors:  Elena Gonzalez-Rey; Nieves Varela; Alejo Chorny; Mario Delgado
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

Review 10.  Immunology of VIP: a review and therapeutical perspectives.

Authors:  R P Gomariz; C Martinez; C Abad; J Leceta; M Delgado
Journal:  Curr Pharm Des       Date:  2001-01       Impact factor: 3.116
View more
  9 in total

1.  VPAC1 and VPAC2 receptor activation on GABA release from hippocampal nerve terminals involve several different signalling pathways.

Authors:  Diana Cunha-Reis; Joaquim Alexandre Ribeiro; Rodrigo F M de Almeida; Ana M Sebastião
Journal:  Br J Pharmacol       Date:  2017-11-29       Impact factor: 8.739

2.  VPAC1 couples with TRPV4 channel to promote calcium-dependent gastric cancer progression via a novel autocrine mechanism.

Authors:  Bo Tang; Jilin Wu; Michael X Zhu; Xuemei Sun; Jingjing Liu; Rui Xie; Tobias Xiao Dong; Yufeng Xiao; John M Carethers; Shiming Yang; Hui Dong
Journal:  Oncogene       Date:  2019-01-28       Impact factor: 9.867

Review 3.  Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.

Authors:  Terry W Moody; Bernardo Nuche-Berenguer; Robert T Jensen
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2016-02       Impact factor: 3.243

4.  The Role of Clinical Proteomics, Lipidomics, and Genomics in the Diagnosis of Alzheimer's Disease.

Authors:  Ian James Martins
Journal:  Proteomes       Date:  2016-03-31

Review 5.  The space where aging acts: focus on the GABAergic synapse.

Authors:  Aleksandra Rozycka; Monika Liguz-Lecznar
Journal:  Aging Cell       Date:  2017-05-12       Impact factor: 9.304

Review 6.  VIP Modulation of Hippocampal Synaptic Plasticity: A Role for VIP Receptors as Therapeutic Targets in Cognitive Decline and Mesial Temporal Lobe Epilepsy.

Authors:  Diana Cunha-Reis; Ana Caulino-Rocha
Journal:  Front Cell Neurosci       Date:  2020-06-12       Impact factor: 5.505

Review 7.  VIP-Expressing GABAergic Neurons: Disinhibitory vs. Inhibitory Motif and Its Role in Communication Across Neocortical Areas.

Authors:  Alfonso Junior Apicella; Ivan Marchionni
Journal:  Front Cell Neurosci       Date:  2022-02-10       Impact factor: 6.147

Review 8.  Targeting prefrontal cortex GABAergic microcircuits for the treatment of alcohol use disorder.

Authors:  Kenneth N Fish; Max E Joffe
Journal:  Front Synaptic Neurosci       Date:  2022-08-29

9.  Alzheimer's disease large-scale gene expression portrait identifies exercise as the top theoretical treatment.

Authors:  Mason A Hill; Stephen C Gammie
Journal:  Sci Rep       Date:  2022-10-13       Impact factor: 4.996
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.